{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:57:49Z","timestamp":1763765869000,"version":"build-2065373602"},"reference-count":89,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,6,29]],"date-time":"2011-06-29T00:00:00Z","timestamp":1309305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2012,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In patients with chronic myeloid leukemia (CML), the hallmark Philadelphia chromosome is the marker of disease that can be detected by conventional metaphase cytogenetics, fluorescence in situ hybridization, or polymerase chain reaction. The current \u201cgold standard\u201d of treatment response is cytogenetic response. Cytogenetic response to imatinib is strongly associated with disease progression and survival. Various strategies aimed at improving cytogenetic response have been explored, such as escalation of imatinib and switching to the newer breakpoint cluster region\/v\u2010abl Abelson murine leukemia viral oncogene (BCR\u2010ABL) inhibitors dasatinib and nilotinib. Data from recent randomized trials of dasatinib and nilotinib as first\u2010line therapy of newly diagnosed chronic\u2010phase CML suggest that these agents are more effective than imatinib in achieving 6\u2010month and 12\u2010month complete cytogenetic responses. However, it is still too early to know whether or not this early response will translate into a long\u2010term survival advantage. In addition, more sensitive assays to detect residual disease also may be associated with improved long\u2010term outcomes. The deepest measure of response\u2014a complete molecular response\u2014may help identify patients who can stop taking imatinib for the short term, although the long\u2010term consequences of this strategy remain unknown. Cancer 2011;. \u00a9 2011 American Cancer Society.<\/jats:p>","DOI":"10.1002\/cncr.26280","type":"journal-article","created":{"date-parts":[[2011,6,30]],"date-time":"2011-06-30T11:17:18Z","timestamp":1309432638000},"page":"300-311","source":"Crossref","is-referenced-by-count":11,"title":["Measuring response to BCR\u2010ABL inhibitors in chronic myeloid leukemia"],"prefix":"10.1002","volume":"118","author":[{"given":"Jerald P.","family":"Radich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,6,29]]},"reference":[{"key":"e_1_2_4_2_2","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell PC","year":"1960","journal-title":"Science."},{"doi-asserted-by":"publisher","key":"e_1_2_4_3_2","DOI":"10.1038\/243290a0"},{"doi-asserted-by":"publisher","key":"e_1_2_4_4_2","DOI":"10.1038\/306277a0"},{"doi-asserted-by":"publisher","key":"e_1_2_4_5_2","DOI":"10.1016\/0092-8674(84)90077-1"},{"doi-asserted-by":"publisher","key":"e_1_2_4_6_2","DOI":"10.1126\/science.2408149"},{"doi-asserted-by":"publisher","key":"e_1_2_4_7_2","DOI":"10.1023\/A:1008349405763"},{"doi-asserted-by":"publisher","key":"e_1_2_4_8_2","DOI":"10.7326\/0003-4819-145-12-200612190-00008"},{"unstructured":"National Cancer Institute National Institutes of Health. Surveillance Epidemiology and End Results web site. Finding Cancer Statistics: Cancer Stat Fact Sheets: Chronic Myeloid Leukemia.http:\/\/seer.cancer.gov\/statfacts\/html\/cmyl. html. Accessed September 3 2010.","key":"e_1_2_4_9_2"},{"doi-asserted-by":"publisher","key":"e_1_2_4_10_2","DOI":"10.1073\/pnas.0510423103"},{"doi-asserted-by":"publisher","key":"e_1_2_4_11_2","DOI":"10.1056\/NEJM199904293401706"},{"unstructured":"National Comprehensive Cancer Network (NCCN). Chronic myelogenous leukemia version 2.2011. NCCN Clinical Practice Guidelines in Oncology.http:\/\/www.nccn.org\/profe ssionals\/physician_gls\/f_guidelines.asp. Accessed September 3 2010.","key":"e_1_2_4_12_2"},{"doi-asserted-by":"publisher","key":"e_1_2_4_13_2","DOI":"10.1200\/JCO.2009.25.0779"},{"doi-asserted-by":"publisher","key":"e_1_2_4_14_2","DOI":"10.1182\/blood-2006-02-005686"},{"doi-asserted-by":"publisher","key":"e_1_2_4_15_2","DOI":"10.1056\/NEJMoa022457"},{"doi-asserted-by":"crossref","unstructured":"DeiningerM O'BrienSG GuilhotF et al.International randomized study of interferon vs STI571 (IRIS) 8\u2010year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) treated with imatinib [abstract]. Blood (ASH Annual Meeting Abstracts).2009;114. Abstract 1126.","key":"e_1_2_4_16_2","DOI":"10.1182\/blood.V114.22.1126.1126"},{"doi-asserted-by":"crossref","unstructured":"MichalletM MorraE SteegmanJ et al.Imatinib resistance and\/or intolerance in clinical practice in Europe. The \u201cUnmet Needs in CML and Ph+ ALL\u201d (UNIC) study [abstract]. Blood (ASH Annual Meeting Abstracts).2007;110 Abstract 1951.","key":"e_1_2_4_17_2","DOI":"10.1182\/blood.V110.11.1951.1951"},{"issue":"20","key":"e_1_2_4_18_2","article-title":"Resistance to imatinib among patients in chronic phase (CP) of chronic myelogenous leukemia (CML) in clinical practice [abstract]","volume":"26","author":"Davis C","year":"2008","journal-title":"J Clin Oncol."},{"doi-asserted-by":"publisher","key":"e_1_2_4_19_2","DOI":"10.1200\/JCO.2007.15.8154"},{"doi-asserted-by":"publisher","key":"e_1_2_4_20_2","DOI":"10.1038\/leu.2008.225"},{"doi-asserted-by":"publisher","key":"e_1_2_4_21_2","DOI":"10.1056\/NEJMoa062867"},{"doi-asserted-by":"publisher","key":"e_1_2_4_22_2","DOI":"10.1182\/blood-2006-02-001495"},{"doi-asserted-by":"publisher","key":"e_1_2_4_23_2","DOI":"10.1038\/leu.2009.38"},{"doi-asserted-by":"publisher","key":"e_1_2_4_24_2","DOI":"10.1182\/blood-2008-06-162388"},{"doi-asserted-by":"publisher","key":"e_1_2_4_25_2","DOI":"10.1182\/blood-2007-07-103523"},{"doi-asserted-by":"publisher","key":"e_1_2_4_26_2","DOI":"10.1056\/NEJMoa030513"},{"doi-asserted-by":"publisher","key":"e_1_2_4_27_2","DOI":"10.1158\/1078-0432.CCR-07-1112"},{"doi-asserted-by":"publisher","key":"e_1_2_4_28_2","DOI":"10.1007\/s00277-008-0548-y"},{"doi-asserted-by":"publisher","key":"e_1_2_4_29_2","DOI":"10.1002\/cncr.23238"},{"doi-asserted-by":"publisher","key":"e_1_2_4_30_2","DOI":"10.1182\/blood-2010-03-273979"},{"doi-asserted-by":"publisher","key":"e_1_2_4_31_2","DOI":"10.1056\/NEJMoa0912614"},{"doi-asserted-by":"publisher","key":"e_1_2_4_32_2","DOI":"10.1056\/NEJMoa1002315"},{"doi-asserted-by":"crossref","unstructured":"RadichJP KopeckyKJ Kamel\u2010ReidS et al.A randomized phase II trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP): the S0325 Intergroup Trial [abstract]. Blood (ASH Annual Meeting Abstracts).2010;116. Abstract LBA\u20106.","key":"e_1_2_4_33_2","DOI":"10.1182\/blood.V116.21.LBA-6.LBA-6"},{"doi-asserted-by":"publisher","key":"e_1_2_4_34_2","DOI":"10.1053\/j.seminhematol.2010.06.007"},{"doi-asserted-by":"publisher","key":"e_1_2_4_35_2","DOI":"10.1158\/1078-0432.CCR-07-0844"},{"doi-asserted-by":"publisher","key":"e_1_2_4_36_2","DOI":"10.1016\/S1470-2045(10)70233-3"},{"doi-asserted-by":"publisher","key":"e_1_2_4_37_2","DOI":"10.1182\/blood-2006-04-017400"},{"doi-asserted-by":"publisher","key":"e_1_2_4_38_2","DOI":"10.1002\/cncr.22936"},{"doi-asserted-by":"publisher","key":"e_1_2_4_39_2","DOI":"10.1182\/blood-2007-01-070045"},{"issue":"20","key":"e_1_2_4_40_2","article-title":"Nilotinib in patients with Philadelphia chromosome\u2010positive chronic myelogenous leukemia in blast crisis (CML\u2010BC) who are resistant or intolerant to imatinib [abstract]","volume":"26","author":"Giles FJ","year":"2008","journal-title":"J Clin Oncol."},{"doi-asserted-by":"publisher","key":"e_1_2_4_41_2","DOI":"10.3324\/haematol.2009.011452"},{"doi-asserted-by":"publisher","key":"e_1_2_4_42_2","DOI":"10.3324\/haematol.13068"},{"doi-asserted-by":"publisher","key":"e_1_2_4_43_2","DOI":"10.3324\/haematol.13529"},{"issue":"1","key":"e_1_2_4_44_2","first-page":"349","article-title":"Dasatinib efficacy in patients with imatinib\u2010resistant\/\u2010intolerant chronic myeloid leukemia in blast phase: 24\u2010month data from the START Program [abstract]","volume":"93","author":"Saglio G","year":"2008","journal-title":"Haematologica."},{"doi-asserted-by":"publisher","key":"e_1_2_4_45_2","DOI":"10.1182\/blood-2008-11-186817"},{"issue":"15","key":"e_1_2_4_46_2","article-title":"Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML\u2010AP) with imatinib (IM) resistance or intolerance: longer follow\u2010up results of a phase II study [abstract]","volume":"27","author":"Le Coutre PD","year":"2009","journal-title":"J Clin Oncol."},{"doi-asserted-by":"publisher","key":"e_1_2_4_47_2","DOI":"10.1200\/JCO.2009.25.4896"},{"doi-asserted-by":"publisher","key":"e_1_2_4_48_2","DOI":"10.1200\/JCO.2009.25.4920"},{"doi-asserted-by":"crossref","unstructured":"KantarjianHM GilesFJ BhallaKN et al.Update on imatinib\u2010resistant chronic myeloid leukemia patients in chronic phase (CML\u2010CP) on nilotinib therapy at 24 months: clinical response safety and long\u2010term outcomes [abstract]. Blood (ASH Annual Meeting Abstracts).2009;113. Abstract 1129.","key":"e_1_2_4_49_2","DOI":"10.1182\/blood.V114.22.1129.1129"},{"doi-asserted-by":"publisher","key":"e_1_2_4_50_2","DOI":"10.1182\/asheducation-2006.1.219"},{"doi-asserted-by":"publisher","key":"e_1_2_4_51_2","DOI":"10.1182\/blood-2002-09-2896"},{"doi-asserted-by":"publisher","key":"e_1_2_4_52_2","DOI":"10.1038\/sj.leu.2404318"},{"doi-asserted-by":"publisher","key":"e_1_2_4_53_2","DOI":"10.1182\/blood-2004-08-3097"},{"doi-asserted-by":"publisher","key":"e_1_2_4_54_2","DOI":"10.1182\/blood-2008-03-144790"},{"doi-asserted-by":"publisher","key":"e_1_2_4_55_2","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"doi-asserted-by":"publisher","key":"e_1_2_4_56_2","DOI":"10.1200\/JCO.2005.05.531"},{"doi-asserted-by":"publisher","key":"e_1_2_4_57_2","DOI":"10.1200\/JCO.2008.16.9953"},{"doi-asserted-by":"publisher","key":"e_1_2_4_58_2","DOI":"10.1016\/S1470-2045(07)70342-X"},{"doi-asserted-by":"publisher","key":"e_1_2_4_59_2","DOI":"10.1126\/science.1062538"},{"doi-asserted-by":"publisher","key":"e_1_2_4_60_2","DOI":"10.1038\/sj.leu.2402741"},{"doi-asserted-by":"publisher","key":"e_1_2_4_61_2","DOI":"10.1182\/blood-2003-12-4276"},{"doi-asserted-by":"publisher","key":"e_1_2_4_62_2","DOI":"10.1038\/sj.leu.2403853"},{"doi-asserted-by":"publisher","key":"e_1_2_4_63_2","DOI":"10.1182\/blood-2007-06-093617"},{"issue":"15","key":"e_1_2_4_64_2","article-title":"Four\u2010year follow\u2010up of patients with chronic\u2010phase chronic myeloid leukemia (CP\u2010CML) receiving 100 mg of dasatinib once daily [abstract]","volume":"28","author":"Shah NP","year":"2010","journal-title":"J Clin Oncol."},{"doi-asserted-by":"crossref","unstructured":"ShahN BahceciE LambertA et al.Resistance outcome and the development of mutations with dasatinib in patients with chronic\u2010phase chronic myeloid leukemia (CML\u2010CP) [abstract]. Blood (ASH Annual Meeting Abstracts).2009;114. Abstract 1122.","key":"e_1_2_4_65_2","DOI":"10.1182\/blood.V114.22.1122.1122"},{"doi-asserted-by":"publisher","key":"e_1_2_4_66_2","DOI":"10.1038\/leu.2009.156"},{"doi-asserted-by":"publisher","key":"e_1_2_4_67_2","DOI":"10.1182\/blood-2009-08-215939"},{"doi-asserted-by":"publisher","key":"e_1_2_4_68_2","DOI":"10.1182\/blood-2009-01-197715"},{"doi-asserted-by":"publisher","key":"e_1_2_4_69_2","DOI":"10.1182\/blood-2007-03-080689"},{"doi-asserted-by":"crossref","unstructured":"RadichJP MartinelliG HochhausA et al.Response and outcomes to nilotinib at 24 months in imatinib\u2010resistant chronic myeloid leukemia patients in chronic phase (CML\u2010CP) and accelerated phase (CML\u2010AP) with and without BCR\u2010ABL mutations [abstract]. Blood (ASH Annual Meeting Abstracts).2009;114. Abstract 1130.","key":"e_1_2_4_70_2","DOI":"10.1182\/blood.V114.22.1130.1130"},{"doi-asserted-by":"publisher","key":"e_1_2_4_71_2","DOI":"10.1200\/JCO.2009.21.8230"},{"doi-asserted-by":"publisher","key":"e_1_2_4_72_2","DOI":"10.1182\/blood-2009-04-214221"},{"doi-asserted-by":"publisher","key":"e_1_2_4_73_2","DOI":"10.1182\/blood-2008-02-141580"},{"doi-asserted-by":"publisher","key":"e_1_2_4_74_2","DOI":"10.3324\/haematol.2009.012781"},{"doi-asserted-by":"publisher","key":"e_1_2_4_75_2","DOI":"10.3324\/haematol.2009.013979"},{"doi-asserted-by":"publisher","key":"e_1_2_4_76_2","DOI":"10.1200\/JCO.2009.25.3724"},{"doi-asserted-by":"publisher","key":"e_1_2_4_77_2","DOI":"10.1182\/blood-2006-07-036012"},{"doi-asserted-by":"publisher","key":"e_1_2_4_78_2","DOI":"10.1182\/blood-2007-10-116475"},{"doi-asserted-by":"publisher","key":"e_1_2_4_79_2","DOI":"10.1016\/j.leukres.2008.07.015"},{"doi-asserted-by":"publisher","key":"e_1_2_4_80_2","DOI":"10.1056\/NEJMoa1004095"},{"doi-asserted-by":"crossref","unstructured":"HehlmannR Jung\u2010MunkwitzS LausekerM et al.Superior CMR\u2010rates with tolerability\u2010adapted imatinib 800 mg vs 400 mg vs 400 mg plus IFN in CML: the randomized German CML\u2010Study IV [abstract]. Blood (ASH Annual Meeting Abstracts).2010;116. Abstract 357.","key":"e_1_2_4_81_2","DOI":"10.1182\/blood.V116.21.357.357"},{"doi-asserted-by":"publisher","key":"e_1_2_4_82_2","DOI":"10.1002\/cncr.25438"},{"doi-asserted-by":"publisher","key":"e_1_2_4_83_2","DOI":"10.3324\/haematol.12265"},{"doi-asserted-by":"publisher","key":"e_1_2_4_84_2","DOI":"10.1182\/blood-2008-12-196543"},{"doi-asserted-by":"publisher","key":"e_1_2_4_85_2","DOI":"10.1200\/JCO.2009.26.3087"},{"doi-asserted-by":"crossref","unstructured":"CortesJ BorthakurG O'BrienS et al.Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML\u2010CP) [abstract]. Blood (ASH Annual Meeting Abstracts).2009;114. Abstract 338.","key":"e_1_2_4_86_2","DOI":"10.1182\/blood.V114.22.338.338"},{"doi-asserted-by":"crossref","unstructured":"CortesJ O'BrienS JonesD et al.Efficacy of nilotinib in patients (pts) with newly diagnosed previously untreated Philadelphia chromosome (Ph)\u2010positive chronic myelogenous leukemia in early chronic phase (CML\u2010CP) [abstract]. Blood (ASH Annual Meeting Abstracts).2009;114Abstract 341.","key":"e_1_2_4_87_2","DOI":"10.1182\/blood.V114.22.341.341"},{"doi-asserted-by":"crossref","unstructured":"RostiG CastagnettiF GugliottaG et al.Excellent outcomes at 3 years with nilotinib 800 mg daily in early chronic phase Ph+ chronic myeloid leukemia (CML): results of a phase 2 GIMEMA CML Working Party clinical trial [abstract]. Blood (ASH Annual Meeting Abstracts).2010;116. Abstract 359.","key":"e_1_2_4_88_2","DOI":"10.1182\/blood.V116.21.359.359"},{"doi-asserted-by":"crossref","unstructured":"HughesTP HochhausA SaglioG et al.ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) [abstract]. Blood (ASH Annual Meeting Abstracts).2010;116. Abstract 207.","key":"e_1_2_4_89_2","DOI":"10.1182\/blood.V116.21.207.207"},{"doi-asserted-by":"crossref","unstructured":"ShahN KantarjianH HochhausA et al.Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) in the DASISION trial: 18\u2010month follow\u2010up [abstract]. Blood (ASH Annual Meeting Abstracts).2010;116. Abstract 206.","key":"e_1_2_4_90_2","DOI":"10.1182\/blood.V116.21.206.206"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.26280","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.26280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T18:59:41Z","timestamp":1760295581000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.26280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,29]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,1,15]]}},"alternative-id":["10.1002\/cncr.26280"],"URL":"https:\/\/doi.org\/10.1002\/cncr.26280","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2011,6,29]]}}}